anonymous
Guest
anonymous
Guest
Like all things, the truth falls somewhere in the middle. I am a rep. The tech is good, especially for Gen 1. Maybe commentators on here don't know the space. The BPH space has imperfect options for patients hence why $ floods to this space. Aquablation is great for glands over 60g. Not worth time to set up etc for smaller. For 100g and over, it will be the gold standard. Negatives are that most Drs and staff will always need reps in most markets forever imo. Lot of case chasing/coverage. The reputation of issues at Procept are true but turned a corner mid 2022. $ for capital and ASRs good to great. Compared to most other companies, both money is better and culture is not terrible. 2023 will be make it or break it time for company and technology. Mgmt is not the best, not very experiences, grasp in the dark a lot, wasted lots of time in 2022 and who knows if they figured it out. TBD